Literature DB >> 21962733

DC maturation and function are not altered by melanoma-derived immunosuppressive soluble factors.

Joel M Baumgartner1, Kimberly R Jordan, Ling-Jia Hu, Cara C Wilson, Anirban Banerjee, Martin D McCarter.   

Abstract

BACKGROUND: Although melanoma can elicit robust tumor antigen-specific immune responses, advanced melanoma is associated with immune tolerance. We have previously described several mechanisms of melanoma-induced immunosuppression, including the skewing of the immune response towards a Th2 cytokine profile and the induction of regulatory T cells. Since dendritic cells (DCs) are potentially important players that can direct other cells of the immune system towards a cytotoxic, humoral, or regulatory phenotype, we hypothesized that melanoma-produced factors directly affect the maturation and function of DCs, influencing the nature and magnitude of the resulting immune response.
MATERIALS AND METHODS: To test this hypothesis, immature myeloid-derived DCs (mdDCs) were derived with cytokines from CD14+ peripheral blood mononuclear cells (PBMCs) and exposed to 20% melanoma-conditioned media (MCM). After 2 d, the expression of maturation markers and the function of these mdDCs, measured by cytokine production, the amount of endocytosis, expression of the inhibitory molecule indoleamine 2,3-dioxygenase (IDO), and the ability to stimulate T cells were determined.
RESULTS: We found that incubation with MCM did not inhibit the expression of maturation markers or IDO, the production of cytokines, the amount of antigen uptake, or the ability to induce T cell proliferation in mixed-lymphocyte reactions by mdDC.
CONCLUSIONS: These results suggest that the immunosuppressive effects of melanoma-produced factors are independent of directly measurable changes in mdDC function or maturation in vitro.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962733      PMCID: PMC4674430          DOI: 10.1016/j.jss.2011.07.040

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  27 in total

Review 1.  Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

Authors:  Nathalie Cools; Peter Ponsaerts; Viggo F I Van Tendeloo; Zwi N Berneman
Journal:  J Leukoc Biol       Date:  2007-08-21       Impact factor: 4.962

2.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Authors:  Nicholas S Wilson; Dima El-Sukkari; Gabrielle T Belz; Christopher M Smith; Raymond J Steptoe; William R Heath; Ken Shortman; José A Villadangos
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

3.  Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

Authors:  A H Enk; H Jonuleit; J Saloga; J Knop
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

4.  Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells.

Authors:  Christian P Gray; Paolo Arosio; Peter Hersey
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

5.  Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage.

Authors:  Ivan Perrot; Dominique Blanchard; Nathalie Freymond; Sylvie Isaac; Benoît Guibert; Yves Pachéco; Serge Lebecque
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli.

Authors:  Michael Jefford; Max Schnurr; Tracey Toy; Kelly-Anne Masterman; Amanda Shin; Tina Beecroft; Tsin Yee Tai; Ken Shortman; Mark Shackleton; Ian D Davis; Phil Parente; Thomas Luft; Weisan Chen; Jonathan Cebon; Eugene Maraskovsky
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

7.  Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.

Authors:  Martin D McCarter; Joel Baumgartner; Guillermo A Escobar; Donald Richter; Karl Lewis; William Robinson; Cara Wilson; Brent E Palmer; Rene Gonzalez
Journal:  Ann Surg Oncol       Date:  2007-06-26       Impact factor: 5.344

Review 8.  The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

Authors:  Andrea Anichini; Claudia Vegetti; Roberta Mortarini
Journal:  Cancer Immunol Immunother       Date:  2004-06-03       Impact factor: 6.968

Review 9.  Dendritic cell immunotherapy for melanoma.

Authors:  Judy C Peng; Ranjeny Thomas; Keith Dredge
Journal:  Rev Recent Clin Trials       Date:  2006-05

Review 10.  Dendritic cell vaccines in melanoma: from promise to proof?

Authors:  W J Lesterhuis; E H J G Aarntzen; I J M De Vries; D H Schuurhuis; C G Figdor; G J Adema; C J A Punt
Journal:  Crit Rev Oncol Hematol       Date:  2008-02-08       Impact factor: 6.312

View more
  1 in total

1.  Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.

Authors:  Lichen Teng; Yongsheng Chen; Dexin Ding; Hongshuang Dai; Guobin Liu; Changfu Li
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.